• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

建立 PNB-qPCR 以定量检测肿瘤切除过程中的最小 ctDNA 浓度。

Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection.

机构信息

Department of Sports Medicine, Rehabilitation and Disease Prevention, Faculty of Social Science, Media and Sport, Johannes Gutenberg-University Mainz, Mainz, Germany.

Department of Anaesthesiology, University Medical Centre Mainz, Mainz, Germany.

出版信息

Sci Rep. 2017 Aug 21;7(1):8876. doi: 10.1038/s41598-017-09137-w.

DOI:10.1038/s41598-017-09137-w
PMID:28827745
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5566323/
Abstract

The analysis of blood plasma or serum as a non-invasive alternative to tissue biopsies is a much-pursued goal in cancer research. Various methods and approaches have been presented to determine a patient's tumour status, chances of survival, and response to therapy from serum or plasma samples. We established PNB-qPCR (Pooled, Nested, WT-Blocking qPCR), a highly specific nested qPCR with various modifications to detect and quantify minute amounts of circulating tumour DNA (ctDNA) from very limited blood plasma samples. PNB-qPCR is a nested qPCR technique combining ARMS primers, blocking primers, LNA probes, and pooling of multiple first round products for sensitive quantification of the seven most frequent point mutations in KRAS exon 2. Using this approach, we were able to characterize ctDNA and total cell-free DNA (cfDNA) kinetics by selective amplification of KRAS mutated DNA fragments in the blood plasma over the course of tumour resection and the surrounding days. Whereas total cfDNA concentrations increased over the surgical and regenerative process, ctDNA levels showed a different scheme, rising only directly after tumour resection and about three days after the surgery. For the first time, we present insights into the impact of surgery on the release of ctDNA and total cfDNA.

摘要

以血浆或血清替代组织活检进行非侵入性分析,是癌症研究中备受关注的目标。已有多种方法和途径被提出,旨在从血清或血浆样本中确定患者的肿瘤状态、生存机会和对治疗的反应。我们建立了 PNB-qPCR(Pooled,Nested,WT-Blocking qPCR),这是一种高度特异的嵌套 qPCR,对检测和定量微量循环肿瘤 DNA(ctDNA)进行了多种改进,仅需非常有限的血浆样本。PNB-qPCR 是一种嵌套 qPCR 技术,结合了 ARMS 引物、阻断引物、LNA 探针和多个第一轮产物的汇集,以敏感地定量 KRAS 外显子 2 中七种最常见的点突变。通过在肿瘤切除过程中和周围几天内选择性扩增 KRAS 突变 DNA 片段,我们能够对 ctDNA 和总游离细胞 DNA(cfDNA)动力学进行特征描述。虽然总 cfDNA 浓度在手术和再生过程中增加,但 ctDNA 水平呈现出不同的模式,仅在肿瘤切除后直接上升,约在手术后三天。我们首次提出了手术对 ctDNA 和总 cfDNA 释放的影响。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a94/5566323/1e31785d09a2/41598_2017_9137_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a94/5566323/0a1f3904b59d/41598_2017_9137_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a94/5566323/1e31785d09a2/41598_2017_9137_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a94/5566323/0a1f3904b59d/41598_2017_9137_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9a94/5566323/1e31785d09a2/41598_2017_9137_Fig2_HTML.jpg

相似文献

1
Establishing PNB-qPCR for quantifying minimal ctDNA concentrations during tumour resection.建立 PNB-qPCR 以定量检测肿瘤切除过程中的最小 ctDNA 浓度。
Sci Rep. 2017 Aug 21;7(1):8876. doi: 10.1038/s41598-017-09137-w.
2
A Targeted Q-PCR-Based Method for Point Mutation Testing by Analyzing Circulating DNA for Cancer Management Care.一种基于靶向定量聚合酶链反应的方法,通过分析循环DNA进行癌症管理护理的点突变检测。
Methods Mol Biol. 2016;1392:1-16. doi: 10.1007/978-1-4939-3360-0_1.
3
Plasma vs. serum in circulating tumor DNA measurement: characterization by DNA fragment sizing and digital droplet polymerase chain reaction.血浆与血清中的循环肿瘤 DNA 测量:通过 DNA 片段大小分析和数字液滴聚合酶链反应进行表征。
Clin Chem Lab Med. 2020 Mar 26;58(4):527-532. doi: 10.1515/cclm-2019-0896.
4
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.对 KRAS 突变的循环肿瘤 DNA 进行纵向监测可预测胰腺癌患者的预后和治疗反应。
PLoS One. 2019 Dec 31;14(12):e0227366. doi: 10.1371/journal.pone.0227366. eCollection 2019.
5
Prognostic value of circulating tumour DNA in patients undergoing curative resection for pancreatic cancer.循环肿瘤DNA在接受胰腺癌根治性切除术患者中的预后价值
Br J Cancer. 2016 Jun 28;115(1):59-65. doi: 10.1038/bjc.2016.175. Epub 2016 Jun 9.
6
Cell-free circulating tumor DNA supplementing tissue biopsies for identification of targetable mutations: Implications for precision medicine and considerations for reconciling results.游离循环肿瘤DNA补充组织活检用于识别可靶向突变:对精准医学的意义及结果协调的考量
Lung Cancer. 2017 Sep;111:135-138. doi: 10.1016/j.lungcan.2017.06.015. Epub 2017 Jun 23.
7
An enzymatic on/off switch-mediated assay for KRAS hotspot point mutation detection of circulating tumor DNA.一种基于酶的开/关开关介导的检测循环肿瘤 DNA 中 KRAS 热点突变的分析方法。
J Clin Lab Anal. 2020 Aug;34(8):e23305. doi: 10.1002/jcla.23305. Epub 2020 Mar 24.
8
Single-Color Digital PCR Provides High-Performance Detection of Cancer Mutations from Circulating DNA.单色数字PCR可对循环DNA中的癌症突变进行高性能检测。
J Mol Diagn. 2017 Sep;19(5):697-710. doi: 10.1016/j.jmoldx.2017.05.003. Epub 2017 Aug 14.
9
Enumeration and targeted analysis of KRAS, BRAF and PIK3CA mutations in CTCs captured by a label-free platform: Comparison to ctDNA and tissue in metastatic colorectal cancer.通过无标记平台捕获的循环肿瘤细胞中KRAS、BRAF和PIK3CA突变的计数及靶向分析:与转移性结直肠癌中的循环肿瘤DNA和组织的比较
Oncotarget. 2016 Dec 20;7(51):85349-85364. doi: 10.18632/oncotarget.13350.
10
RAS/BRAF Circulating Tumor DNA Mutations as a Predictor of Response to First-Line Chemotherapy in Metastatic Colorectal Cancer Patients.RAS/BRAF 循环肿瘤 DNA 突变作为预测转移性结直肠癌患者一线化疗反应的标志物。
Can J Gastroenterol Hepatol. 2018 Mar 7;2018:4248971. doi: 10.1155/2018/4248971. eCollection 2018.

引用本文的文献

1
Development and validation of an ultrasensitive qPCR method to identify and quantify EGFR T790M in cell-free DNA.一种用于鉴定和定量游离DNA中EGFR T790M的超灵敏qPCR方法的开发与验证
Bioanalysis. 2025 Jan;17(1):49-62. doi: 10.1080/17576180.2025.2451527. Epub 2025 Jan 15.
2
New Perspectives on the Role of Liquid Biopsy in Bladder Cancer: Applicability to Precision Medicine.液体活检在膀胱癌中的作用新视角:对精准医学的适用性
Cancers (Basel). 2024 Feb 16;16(4):803. doi: 10.3390/cancers16040803.
3
Evidence for the utility of cfDNA plasma concentrations to predict disease severity in COVID-19: a retrospective pilot study.

本文引用的文献

1
Release of bulk cell free DNA during physical exercise occurs independent of extracellular vesicles.体育锻炼期间游离细胞外DNA的释放独立于细胞外囊泡发生。
Eur J Appl Physiol. 2015 Nov;115(11):2271-80. doi: 10.1007/s00421-015-3207-8. Epub 2015 Jul 1.
2
Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery.结直肠癌手术后利用循环肿瘤 DNA 监测疾病负担的分析。
Gut. 2016 Apr;65(4):625-34. doi: 10.1136/gutjnl-2014-308859. Epub 2015 Feb 4.
3
Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment.
cfDNA 血浆浓度预测 COVID-19 疾病严重程度的效用证据:一项回顾性试点研究。
PeerJ. 2023 Sep 18;11:e16072. doi: 10.7717/peerj.16072. eCollection 2023.
4
Blood-based liquid biopsy: insights into early detection, prediction, and treatment monitoring of bladder cancer.基于血液的液体活检:膀胱癌早期检测、预测和治疗监测的新视角。
Cell Mol Biol Lett. 2023 Apr 4;28(1):28. doi: 10.1186/s11658-023-00442-z.
5
Full pathogen characterisation: species identification including the detection of virulence factors and antibiotic resistance genes via multiplex DNA-assays.完整的病原体鉴定:通过多重DNA检测进行物种鉴定,包括检测毒力因子和抗生素耐药基因。
Sci Rep. 2021 Mar 16;11(1):6001. doi: 10.1038/s41598-021-85438-5.
6
Circulating Tumor DNA as a Preoperative Marker of Recurrence in Patients with Peritoneal Metastases of Colorectal Cancer: A Clinical Feasibility Study.循环肿瘤DNA作为结直肠癌腹膜转移患者复发的术前标志物:一项临床可行性研究
J Clin Med. 2020 Jun 4;9(6):1738. doi: 10.3390/jcm9061738.
7
Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers.利用无细胞 DNA:用于泌尿生殖系统癌症液体活检的血浆循环肿瘤 DNA。
Nat Rev Urol. 2020 May;17(5):271-291. doi: 10.1038/s41585-020-0297-9. Epub 2020 Mar 17.
8
Circulating cell-free high mobility group AT-hook 2 mRNA as a detection marker in the serum of colorectal cancer patients.循环游离高迁移率族AT钩蛋白2信使核糖核酸作为结直肠癌患者血清中的一种检测标志物
J Clin Lab Anal. 2018 May;32(4):e22332. doi: 10.1002/jcla.22332. Epub 2017 Sep 26.
对难治性抗表皮生长因子受体(EGFR)治疗的结直肠癌患者循环肿瘤DNA中的克隆选择模式进行表征。
Ann Oncol. 2015 Apr;26(4):731-736. doi: 10.1093/annonc/mdv005. Epub 2015 Jan 26.
4
Circulating tumor DNA as a liquid biopsy for cancer.循环肿瘤 DNA 作为癌症的液体活检。
Clin Chem. 2015 Jan;61(1):112-23. doi: 10.1373/clinchem.2014.222679. Epub 2014 Nov 11.
5
Double-stranded DNA in exosomes: a novel biomarker in cancer detection.外泌体中的双链DNA:癌症检测中的一种新型生物标志物。
Cell Res. 2014 Jun;24(6):766-9. doi: 10.1038/cr.2014.44. Epub 2014 Apr 8.
6
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage.一种用于定量循环肿瘤DNA的超灵敏方法,具有广泛的患者覆盖范围。
Nat Med. 2014 May;20(5):548-54. doi: 10.1038/nm.3519. Epub 2014 Apr 6.
7
Direct quantification of cell-free, circulating DNA from unpurified plasma.直接定量未纯化血浆中的游离循环DNA。
PLoS One. 2014 Mar 3;9(3):e87838. doi: 10.1371/journal.pone.0087838. eCollection 2014.
8
Liquid biopsies: genotyping circulating tumor DNA.液体活检:循环肿瘤 DNA 的基因分型。
J Clin Oncol. 2014 Feb 20;32(6):579-86. doi: 10.1200/JCO.2012.45.2011. Epub 2014 Jan 21.
9
Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients.多重皮升级微滴数字 PCR 检测结直肠癌患者血浆循环 DNA 中的 KRAS 突变。
Clin Chem. 2013 Dec;59(12):1722-31. doi: 10.1373/clinchem.2013.206359. Epub 2013 Aug 12.
10
Liquid biopsy: monitoring cancer-genetics in the blood.液体活检:监测血液中的癌症基因突变。
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84. doi: 10.1038/nrclinonc.2013.110. Epub 2013 Jul 9.